We are live on ! Find out more
GRCE icon

Grace Therapeutics
GRCE

15 hedge funds and large institutions have $1.47M invested in Grace Therapeutics in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 15 → 15 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.33% less ownership

Funds ownership: 3.9% → 3.57% (-0.33%)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

60% less capital inflows, than outflows

Capital inflows: $112K | Capital outflows: $279K

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$95.3K
2
Renaissance Technologies
Renaissance Technologies
New York
+$11.1K
3
Virtu KCG Holdings
Virtu KCG Holdings
New York
+$3.86K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$1.34K

Top Sellers

Rank Fund Capital Flow
1
Fiera Capital (Canada)
Fiera Capital (Canada)
Quebec, Canada
-$140K
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$130K
3
Citadel Advisors
Citadel Advisors
Florida
-$9.6K
4
UBS Group
UBS Group
Switzerland
-$335

GRCE Hedge Fund Activity: Q3 2015 in Review

15 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2015, worth a combined $1.47M — down 21% from $1.86M a quarter earlier.

Fund positioning in GRCE was balanced in Q3 2015: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 4 trimmed.

The largest buyer was 1832 Asset Management, opening a new position worth an estimated $95.3K. The largest seller was Fiera Capital (Canada), cutting an estimated $140K.

  • 15 institutional investors held Grace Therapeutics (GRCE) as of Q3 2015, unchanged from Q2 2015.
  • Funds reported $1.47M of Grace Therapeutics stock for Q3 2015, down 21% quarter-over-quarter.
  • 2 funds opened new Grace Therapeutics positions in Q3 2015 and 2 closed out, a net change of 0 holders.
  • The largest Grace Therapeutics buyer in Q3 2015 was 1832 Asset Management, an estimated $95.3K added.
  • The largest Grace Therapeutics seller in Q3 2015 was Fiera Capital (Canada), an estimated $140K sold.

Based on aggregated 13F filings for Q3 2015.